Possible 8-Week Cure for Patients with Hepatitis C
Investigational Hepatitis C Drug Granted Priority Review
By Jennifer Barrett
The FDA has accepted AbbVie’s New Drug Application (NDA) for and granted priority review to its investigational, pan-genotype regimen of glecaprevir/pibrentasvir (G/P). The treatment is being evaluated for its ability to treat all major genotypes (GT1-6) of chronic hepatitis C virus (HCV).
The NDA is based on data from 8 studies which evaluated more than 2300 patients in 27 countries across all major HCV genotypes and special populations.
Continue reading this entire article: